Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 1Phase 2 1

Status

Completed 5Recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 20Tumor-Agnostic 5Other solid neoplasm 5Thoracic 3CNS 3Breast 3Head & Neck 2Gynecologic 2Sarcoma 1Endocrine 1

Conditions

Neoplasms 4Carcinoma, Squamous Cell 1

Interventions

Paclitaxel 57Gemcitabine 51Carboplatin 51Surveys and Questionnaires 48Docetaxel 37Bevacizumab 37pembrolizumab 33Nivolumab 29Cisplatin 28Fluorouracil 24Capecitabine 23Irinotecan 22Erlotinib Hydrochloride 22Sorafenib 20Leucovorin 19Afatinib 19Radiotherapy 18Pemetrexed 18Oxaliplatin 17Trastuzumab 16Ipilimumab 15regorafenib 14Blood Specimen Collection 14130-nm albumin-bound paclitaxel 14olaparib 13Interviews as Topic 13Cetuximab 13Albumin-Bound Paclitaxel 13atezolizumab 12Sunitinib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × irinotecan sucrosofate × Tumor-Agnostic × Clear all
NCT03719924 2025-01-08

OESIRI

Federation Francophone de Cancerologie Digestive

Phase 2 Completed
106 enrolled
Tumor-Agnostic

Carcinoma, Squamous Cell

NCT03665441 2022-10-18

Trybeca-1

ERYtech Pharma

Phase 3 Completed
512 enrolled 19 charts
Tumor-Agnostic

Neoplasms

NCT00062842 2020-03-04

Study of Irinotecan on a Weekly Schedule in Children

Baylor College of Medicine

Phase 1 Completed
23 enrolled
Tumor-Agnostic

Neoplasms

NCT00364143 2019-07-05

Safety Study of IHL-305 (Irinotecan Liposome Injection) to Treat Advanced Solid Tumors

Yakult Honsha Co., LTD

Phase 1 Completed
40 enrolled
Tumor-Agnostic

Neoplasms

NCT02640365 2017-01-31

DOUBLIRI

GERCOR - Multidisciplinary Oncology Cooperative Group

Phase 1 Completed
10 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡